HC Wainwright & Co. Reiterates Buy on IGM Biosciences, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on IGM Biosciences (NASDAQ:IGMS) and maintained a $22 price target.
June 06, 2023 | 10:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on IGM Biosciences and maintained a $22 price target.
The reiteration of a Buy rating and maintenance of a $22 price target by HC Wainwright & Co. analyst Robert Burns indicates a positive outlook for IGM Biosciences. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100